Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNICORN: Osimertinib for uncommon EGFR-mutated NSCLC
jRCTs071200002Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoint: Objective response rate. Started Apr 2020; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs071200002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071200002.